Inmunómica traslacional en neoplasias hematológicas
Icahn School of Medicine at Mount Sinai
Nueva York, Estados UnidosPublicacións en colaboración con investigadores/as de Icahn School of Medicine at Mount Sinai (24)
2024
-
Correction to: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review (Blood Cancer Journal, (2024), 14, 1, (24), 10.1038/s41408-023-00966-9)
Blood Cancer Journal
-
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
Blood Cancer Journal, Vol. 14, Núm. 1
-
Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting
Clinical Lymphoma, Myeloma and Leukemia
-
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202
2023
-
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
Blood cancer journal
-
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma
Future Oncology, Vol. 19, Núm. 27, pp. 1823-1840
2022
-
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
Blood cancer discovery, Vol. 3, Núm. 4, pp. 273-284
-
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
The New England journal of medicine, Vol. 387, Núm. 24, pp. 2232-2244
-
Teclistamab in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505
2021
-
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study
The Lancet Oncology, Vol. 22, Núm. 1, pp. 142-154
-
Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
Journal of Clinical Pharmacology, Vol. 61, Núm. 5, pp. 614-627
-
Idecabtagene vicleucel in relapsed and refractory multiple myeloma
New England Journal of Medicine, Vol. 384, Núm. 8, pp. 705-716
-
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)
Haematologica, Vol. 106, Núm. 6, pp. 1725-1732
-
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study
British Journal of Haematology, Vol. 192, Núm. 5, pp. 869-878
-
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
The Lancet, Vol. 398, Núm. 10301, pp. 665-674
2020
-
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
The Lancet Oncology, Vol. 21, Núm. 2, pp. 207-221
-
Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set
Blood, Vol. 136, Núm. 26, pp. 3033-3040
-
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
Blood Cancer Journal, Vol. 10, Núm. 11
2019
-
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
Blood, Vol. 134, Núm. 5, pp. 421-431
-
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
Blood, Vol. 134, Núm. 8, pp. 668-677